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I. Executive Summary 
 
Problem: 
Asthma is a chronic pulmonary disease that occurs in approximately 10 percent of the population 
worldwide and is associated with a significant increase in direct medical expenditures. 
Levalbuterol and racemic albuterol are two short-acting β2-agonists (SABA) prescribed for the 
treatment of asthma. Racemic albuterol has been used for more than 40 years but is associated 
with several side effects including tremor. When levalbuterol was approved in 2005 its 
manufacturer and several studies suggested that using levalbuterol results in better respiratory 
parameters, fewer hospitalizations, less adverse effects and therefore, lower overall treatment 
costs and hence less need for β-adrenergic agonist treatment. However, this pattern of results is 
not universal and some studies suggest no significant difference in clinical endpoints. With these 
conflicting data it is difficult to agree over the choice of which SABA; levalbuterol or racemic 
albuterol that should be used. The purpose of this study therefore is to compare asthma-related 
health care expenditures and treatment outcomes after initiation of maintenance treatment with 
levalbuterol or albuterol  
 
Research Strategy: 
This was a retrospective cohort study of pharmacy and medical claims from the Kentucky 
Medicaid MMIS database consisting of patients with asthma who received treatment with a short 
acting beta agonist (SABA); albuterol or levalbuterol between January 1, 2000 and December 
31, 2008. Descriptive statistics were used to characterize the study group. Difference over time 
analyses were used to generate an estimate of the impact of using levalbuterol on asthma-related 
and total healthcare expenditure. Multiple linear regression analyses were used to obtain a more 
precise measure of the financial impact of using levalbuterol. 
 
Major Findings: 
The baseline characteristics for the two patient populations were significantly different. The 
levalbuterol group was much younger with an average age of 11 years whereas the racemic 
albuterol group had an average age of 25 years. The levalbuterol group on average spent $US281 
less on asthma related healthcare costs than the racemic albuterol group (p <0.001). The 
levalbuterol group had an adjusted savings of $US1317  per patient for total healthcare 
expenditures (p <0.001) compared with the racemic albuterol group. This was mainly due to a  
large and statistically significant reduction in hospital visits costs of $US788 (p <0.001). The 
number of emergency department visits, physician visits, and hospitalizations increased 
statistically for both groups and there was a general shift from less severe to more severe asthma 
for both groups over time.  
 
Recommendations: 
This study showed that the added cost of using levalbuterol was more than offset by reductions 
in other types of healthcare expenditures. Levalbuterol should therefore become the drug of 
choice for exacerbation of asthma in the Kentucky Medicaid population. Randomized double-
blind studies need to be done to verify these results and to determine whether the difference in 
total costs is due to fewer adverse effects, better adherence or better long-term efficacy. 
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I. Problem Statement 
Asthma is a chronic pulmonary disease characterized by reversible airway obstruction and 
inflammation that occurs in 8 to 10 percent of the population.(Busse et al, 2004) There are an 
estimated 300 million patients with asthma worldwide (Masoli et al., 2004) including 22 million 
in the U.S.(CDC, 2006) The prevalence of asthma is increasing in most countries, especially 
among children, and if the current trends continue, it is estimated that there may be an additional 
100 million asthmatics by 2025.(Bateman et al, 2008) Each year in the U.S., about 11 million 
patients have an acute deterioration of respiratory symptoms following a respiratory viral 
infection or exposure to environmental allergens or irritants. (CDC, 2008)  
While most asthma exacerbations are managed in the outpatient setting, more severe 
exacerbations may require hospitalization and are responsible for a substantial proportion of 
healthcare expenditures for asthma. In the U.S., severe asthma exacerbations lead to over 
400,000 hospitalizations each year and these hospitalizations constitute about one-third of the 
total annual asthma-related healthcare expenditures. (American lung Association, 2005) Asthma 
in both subpopulations, children and adults, is associated with a significant increase in direct 
medical expenditures, with the overall annual direct medical expenditure associated with asthma 
estimated at approximately $37.2 billion in 2007 U.S. dollars. (Kamble, 2009) 
Mainstay therapy for asthma includes the use of β2-receptor agonists for reversal of acute 
airway obstruction and asthma exacerbations such as cough. Thus, up to two thirds of asthma 
patients in the United States have received β2-receptor agonist therapy during the past 20 years. 
(Reed et al, 1985) Levalbuterol and racemic albuterol are two commonly prescribed short-acting 
β2-agonists used for the treatment of asthma. Racemic albuterol is formulated as a racemic 
mixture of equal parts of two mirror-image enantiomers, the (R)-and (S)-enantiomers, with the 
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(R)-enantiomer (levalbuterol) being responsible for bronchodilation and the bronchoprotective 
properties of the drug. (Lotval et al, 2001)  
The relative safety of levalbuterol and racemic albuterol is quite controversial. 
(Ozminkowski et al, 2007) The (S)-isomer was initially believed to be inert, and its presence in 
the racemic drug of no consequence, but it is now thought to compress the potency and 
foreshorten the duration of (R)-albuterol. (Handley et al, 2000) Despite these in vitro and animal 
studies, studies in humans have not always shown clinically meaningful effects. Other studies 
suggest that racemic albuterol was associated with bothersome adverse effects, whereas, with 
levalbuterol, the adverse effects were less frequent and symptom relief was perceived to be 
better; which may lead to higher overall satisfaction with levalbuterol treatment. This is believed 
to be due to the fact that inhalation of racemic albuterol, results in the persistence of circulating 
S-albuterol 12 times longer than levalbuterol, suggesting potential for the paradoxical effects 
observed clinically. (Ameredes, 2009) Results from an in vitro study also demonstrated that 
levalbuterol is 2-fold more potent than racemic albuterol and 90- to 100-fold more potent than S-
albuterol. (Penn et al, 1996)  Accordingly, pure (R)-albuterol provides bronchodilation at lower 
doses than racemic albuterol, allowing for fewer β-adrenergic-mediated side effects. (Handley et 
al, 2000) 
Levalbuterol is being lauded as a safer form of albuterol, and as is the case with most new 
therapies, this claimed superiority comes at a price. Levalbuterol can cost as much as 5 times 
more than a comparable generic racemic albuterol nebulizer solution. (Asmus, 2000) With regard 
to efficacy, some authors have found or suggested that using levalbuterol results in better 
respiratory parameters, fewer hospitalizations, and therefore, lower overall treatment costs and 
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less need for β-adrenergic agonist treatment. However, this pattern of results is not universal and 
some studies suggest no significant difference in clinical endpoints. (Ozminkowski et al, 2007) 
With the literature now rife with conflicting data regarding potential anti-therapeutic effects of 
(S)-albuterol and purported advantages of levalbuterol, both in efficacy and in safety, it is 
difficult for doctors, patients, health plans, and policy makers to agree over the choice of which 
SABA; levalbuterol or racemic albuterol that should be used. This study addresses the potential 
consequences of short-acting β2-adrenoceptor agonist drug choice for Kentucky Medicaid 
patients from a financial perspective. The purpose of this study therefore is to compare asthma-
related health care expenditures and treatment outcomes in the year after initiation of 
maintenance treatment with levalbuterol or albuterol in the Kentucky Medicaid population. 
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II. Literature Review 
 
Clinical studies suggest no overwhelming superiority of levalbuterol over racemic 
albuterol; however, levalbuterol’s effects may be greatest in moderate to severe asthma patients, 
especially with racemic albuterol overuse. (Ameredes et al, 2009)  Several small (N<33) human 
studies have been conducted but the results have been somewhat heterogeneous. (Ameredes et al, 
2009) In one initial study levalbuterol suppressed bronchospasm more effectively than racemic 
albuterol and (S)-albuterol. (PerrinFayolle et al, 1996) Subsequent studies reported equivalencies 
of levalbuterol to racemic albuterol, with some indicating that the bronchodilatory effect of 
levalbuterol, 1.25 mg, was equivalent to that of racemic albuterol, 2.5 mg, with (S)-albuterol 
having little measurable effect. (Cockcroft, 1997; Cockcroft et al, 1999; Ramsay et al, 1999) 
However, the above studies were short-term and because of the effects of levalbuterol within the 
racemate, such a short-term approach would be expected to show equivalently strong effects. 
This approach did not provide an assessment of differences between racemic albuterol and 
albuterol isomers with chronic use.  
One of the landmark clinical trials comparing levalbuterol and racemic albuterol was that 
of Nelson et al. (Nelson et al, 1998), in which patients were randomly assigned to levalbuterol, 
0.63 or 1.25 mg, or racemic albuterol 1.25 or 2.5 mg. The trial was designed to prove the 
equivalency of equal mass levels of levalbuterol, with and without (S)-albuterol present. The 
results indicated significantly greater improvements in forced expiratory volume in 1 second 
(FEV1) in the levalbuterol groups compared with the dose-equivalent racemic groups. 
Interestingly, the dose that provided numerically equivalent bronchodilation as that seen with the 
2.5 mg of racemic albuterol was 0.63 mg of levalbuterol, not 1.25 (the mass equivalent dose). 
Thus the data have been interpreted as showing a detrimental effect of (S)-albuterol.  
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Several clinical studies have been conducted in pediatric asthma patients. A randomized, 
placebo-controlled comparator trial reported no significant differences between the drugs with 
respect to FEV1. (Gawchick, 1999) Another double-blind, placebo-controlled, randomized trial 
concluded that no difference was found in bronchodilation with levalbuterol compared to 
racemic albuterol. There was no dose-response relationship in children with mild to moderate 
asthma but a dose-response relationship was observed for levalbuterol in children with more 
severe asthma. (Milgrom, 2001) In a sample of acutely asthmatic children aged 6–18 years 
presenting to a tertiary hospital emergency department (ED), the authors concluded that the more 
expensive Levalbuterol did not shorten ED length of stay, reduce number of nebulized 
treatments, improve peak expiratory flow (PEF) measurements, reduce symptomatic 
complications, or reduce unplanned return visits for asthma management when compared to 
racemic albuterol plus ipratropium (RAC/IB). Use of LEV did provide some benefit as 
demonstrated by its association with less tachycardia compared to RAC/IB. (Ralston, 2005) 
A randomized, double-blind, age-stratified trial of patients presenting to the ED with the 
primary outcome being hospital admission rate found that hospitalization rate was significantly 
lower in the levalbuterol group than in the racemic albuterol group (36%, 45 %, P = 0.02). The 
adjusted relative risk of admission in the racemic group compared with the levalbuterol group 
was 1.25. Hospital length of stay was not significantly shorter in the levalbuterol group and no 
significant adverse events occurred in either group. The authors concluded that substituting 
levalbuterol for racemic albuterol in the ED management of acute asthma significantly reduced 
the number of hospitalizations. (Carl et al, 2003) A study done by Nowak et al. supported the 
idea that levalbuterol could be preferable to racemic albuterol in the emergent treatment of acute 
asthma. FEV1 improvement was greater following Levalbuterol compared with racemic 
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albuterol, both after dose 1 and cumulatively over the entire treatment period. Other aspects of 
the study suggest that patients with high (S)-albuterol plasma levels have slower improvement in 
FEV1 and a greater likelihood of hospital admission. (Nowak et al, 2006) 
In several studies levalbuterol resulted in FEV1 values that were comparable with or better 
than those observed with racemic albuterol and β-mediated side effects were lower for an 
equipotent dose of levalbuterol when compared with racemic albuterol. Treatment costs were 
lower with levalbuterol mainly because of a decrease in hospital admissions. The authors 
concluded that levalbuterol treatment in the ED resulted in higher patient discharge rates and 
may be a cost-effective alternative to racemic albuterol. In one study the authors concluded that 
compared with patients treated with racemic albuterol, those treated with levalbuterol required 
less medication, had shorter lengths of hospital stay, had decreased costs for nebulizer therapy 
and hospitalization, and appeared to have a more prolonged therapeutic benefit. Regression 
analysis indicated that levalbuterol was associated with a length-of-stay savings of 0.91 days (p = 
0.015), a total cost savings of $556 (p = 0.013), and a decrease in the likelihood of hospital 
readmission of 67% (p = 0.056) (Truit et al, 2003) 
Several studies however resulted in similar improvements in FEV1, and tolerability, but 
plasma (R)-albuterol levels and mean heart rate were less with levalbuterol. (Tripp et al, 2008; 
Hamilos et al, 2007) No differences were detected between groups after the first, third, and fifth 
nebulizer treatments in the primary outcome of improvement in asthma score or percentage of 
predicted FEV1, and no differences were found in the secondary outcomes of the number of 
nebulizer treatments given; length of care; rate of hospitalization; and changes in pulse rate, 
respiratory rate, and pulse oximetry readings. There were no differences between groups in 
adverse effects. (Qureshi et al, 2005) 
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III. Research Strategy and Methods 
 
Study design: 
 
This analysis was conducted as a retrospective cohort study of pharmacy and medical 
claims from the Kentucky Medicaid (MMIS) database of patients with asthma who received 
treatment with a short acting beta agonist (SABA), albuterol or levalbuterol between January 1, 
2000 and December 31, 2008. Pharmacy data were identified by using the American Hospital 
Formulary Service code and the National Drug Code. Included in the pharmacy data were the 
drug dispensed, date the drug was dispensed, quantity and days supplied and amount paid. 
Medical claims were identified by using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes. Included in the medical claims data were the 
date of service, point of service, and amount paid. In addition, data were available for date of 
birth, gender, and plan enrollment time for each patient. 
 
Study population: 
 
To be eligible for inclusion in the study patients were required to have at least 1 
pharmacy claim for either albuterol or levalbuterol between January 1, 2000 and December 31, 
2008 with a primary ICD-9-CM code (493.xxx) for asthma at anytime in the database. The first 
pharmacy claim for albuterol or levalbuterol was designated as the index date. Enrollment in the 
plan had to be continuous for at least 24 months: 12 months before the first index prescription 
(baseline preindex period) and 12 months after (treatment postindex period). Identified patients 
could not have received albuterol and levalbuterol in the 12-month baseline preindex period to 
ensure that prior use of the drugs was not a confounding factor on asthma control and hence 
costs. In addition, several exclusion criteria were applied: any medical service claim coded 
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during the preindex period (or on the index date) with a primary or secondary diagnosis of 
chronic obstructive pulmonary disease [ICD-9-CM] codes 491.xx, 492.xx, 493.2x, 494.xx, 
496.xx, 770.2), pulmonary hypertension (416.xx), pulmonary embolism (415.xx), or other 
pulmonary circulatory disorder (417.xx) These comorbid conditions were excluded because they 
may impede asthma management and will have an impact on treatment outcomes. 
 
Outcome: 
 
The primary outcome was trends over time in total medical expenditures and asthma-
related expenditures for levalbuterol versus racemic albuterol patients. The secondary outcome 
was index of asthma control determined by the number of asthma controller medication needed 
and number of office visits, emergency department visits and hospitalizations.  Total and asthma-
related medical and pharmacy patient claims data were tabulated over the baseline and treatment 
periods (12 months each). 
 
Analysis 
 
This study examines treatment costs and asthma control of levalbuterol and albuterol over 
time. The number of prescribed controller medications (CM), emergency room visits, physician 
visits and hospitalizations were used as indices of asthma severity. Trends over time in total 
medical expenditures and asthma-related expenditures were compared for levalbuterol versus 
racemic albuterol patients. Trends over time were determined by post-index period minus pre-
index period expenditures. This provided an initial unadjusted estimate of the relative cost 
impact of taking levalbuterol. Multiple linear regression analyses were used to account for the 
differences in the characteristics of the sample members and to compare the differences in pre- 
and post-index asthma control. All of the regression analyses were adjusted for differences due 
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to age, gender, race, and pre-index expenditures. Throughout the study continuous variables were 
analyzed using t-tests and characterized by mean and standard deviation. Categorical variables 
were analyzed using the chi-square test and characterized by frequency and percentage within 
each category. All statistical analyses were performed at a significance level of 0.05 in STATA 
version 9.1. 
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IV. Results 
 
Sample characteristics for the pre-index period of the 21,511 levalbuterol patients and the 
497,160 racemic albuterol patients are shown in Table I. The baseline characteristics for the two 
patient populations were significantly different.  
Table I: Pre-index Characteristics of patients initiating albuterol or levalbuterol 
 
 
 
Levalbuterol 
(n=21,511) 
Racemic Albuterol 
(n=497,160) 
 
P-value 
 
Mean ± SD (yrs) 
 
11.19 ± 20.7 
 
24.62 ± 24.2 
 
0.000 
Gender no. (%)  
9,801 (45.6) 
11,710 (54.4) 
 
273,167 (54.9)  
223,993 (45.1) 
  
} 0.000 
  Females 
 Males 
Race no. (%)  
 
18,138 (84.3) 
1,362 (6.33) 
36 (0.17) 
35 (0.16) 
140 (0.65) 
1,800 (8.37) 
 
 
398,524 (80.2) 
54,667 (11.0) 
808 (0.16) 
990 (0.20) 
3,526 (0.71) 
38,645 (7.77) 
 
 } 0.000 
 
  
White 
African American 
Hispanic/Latino 
Asian or Pacific Islander  
Other race or ethnicity 
Not Provided 
 
No (%) Controlling drugs (CD)  
 
21,454 (99.7) 
1,194 (5.55) 
11,590 (53.9) 
21,501 (99.9) 
68 (0.32) 
409 (1.90) 
4 (0.0002) 
3,618 (16.8) 
 
 
457,310 (92.0) 
45,600 (96.7) 
192,035 (38.6) 
497,038 (100) 
3,170 (0.64) 
16,481 (3.32) 
101 (0.0002) 
82,386 (16.6) 
 
 
0.000 
0.000 
0.000 
0.052 
0.000 
0.000 
0.862 
0.338 
  
LABA 
LABA + ICS 
ICS/OCS 
LRA 
MCS 
Xanthenes 
Omalizumab 
Epinephrine 
Severity of asthma (%)  
1(0.00005) 
42 (0.20) 
8,587 (39.9) 
13,081 (60.8) 
 
2 (0.000004) 
19,103 (3.84) 
234,125 (47.1) 
243,930 (49.1) 
 
}0.0000 
 Intermittent 
Mild 
Moderate 
Severe 
 
p-values for gender and race  are based on independence chi-square tests. All others are t-tests. LABA, Long 
acting beta agonist; ICS, inhaled corticosteroid;, OCS, oral corticosteroid; LRA, Leukotriene receptor 
antagonists; MCS, mast cell stabilizers 
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The levalbuterol group was much younger with an average age of 11 years whereas the 
racemic albuterol group had an average age of 25 years. There was not much difference in the 
age range between the two groups. The age ranged from 0 - 101 years in the levalbuterol group 
and 0 - 107 years in the racemic albuterol group. The levalbuterol group had more males (54.4%) 
whereas the racemic albuterol group had more females (54.9%). The racial distribution of the 
two groups was significantly different, but both groups had a racial population that reflected the 
Medicaid population with Caucasians accounting for 84.3% in the levalbuterol group and 80.2% 
in the racemic albuterol group. Race was not recorded for 8.37% of the levalbuterol group and 
7.77% of the racemic albuterol group.  
The class of drugs most utilized by both groups was the leukotriene receptor antagonists, 
99.9% of the levalbuterol group and 100% of the racemic albuterol group. Ninety-nine percent of 
the levalbuterol population had a pharmacy claim for a long acting beta agonist. Ninety-two 
percent of the racemic group had a pharmacy claim for a long acting beta agonist and 96.7% had 
a claim for a long acting beta agonists/corticosteroids combination. The number of patients on a 
leukotriene receptor antagonist, omalizumab and epinephrine was not significantly different 
between the two groups (p = 0.052, 0.862, 0.338 respectively). 
Severity of asthma was determined by the number of controller medications that the patient 
was taking. A patient was determined to have intermittent asthma if they were not taking any 
medication to control their asthma, mild if they were taking one controller medication, moderate 
if they were taking two, and severe if they were taking at least three medications to help control 
their asthma. Sixty-one percent of the levalbuterol population had severe asthma whereas the 
racemic group had a fairly even distribution between moderate asthma (47.1%) and severe 
asthma (49.1%). 
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Table II: Age Category Distribution of Patients Initiating Levalbuterol and 
Racemic Albuterol 
Age Category yrs. (%) Levalbuterol group 
(n=21,511) 
Racemic Albuterol group 
(n=497,160) 
0 – 4  13,027 (60.6) 128,508 (25.8) 
5 – 11  4,418 (20.5) 101,519 (20.4) 
12 – adults  4,066 (18.9) 267,133 (53.7) 
 
The Guidelines for the Diagnosis and Management of Asthma has separate treatment 
guidelines for the three different age groups listed in table II. The type and number of drugs 
initiated at each step during asthma therapy differs depending on the age of the patient. Sixty 
percent of the levalbuterol group was between the ages of 0 – 4 years while 53.7% of the racemic 
group was ≥ 12 years. Roughly 20% of the population of both groups was between the ages 5 – 
11 years. 
 
Table III: Patient Characteristics based on Age Groups 
 
 Levalbuterol group (n=21,511) 
Age Groups (yrs) 
Racemic Albuterol group (487,160) 
Age Groups (yrs) 
 0 – 4 5 – 11 ≥ 12 0 – 4 5 – 11 ≥ 12 
 
Females no. (%) 
 
5,267 (53.7) 
 
1,807 (18.4) 
 
2,727 (27.8) 
 
51,255 (18.8) 
 
41,859 (15.3) 
 
180,053 (65.9) 
 
No. (%) Controlling Drugs 
LABA 12,992 (60.6) 4,406 (20.5) 4,056 (18.9) 128,124 (28.0) 100,948 (22.1) 228,238 (49.9) 
LABA + ICS 44 (3.69) 363 (30.4) 787 (65.9) 727 (1.59) 7,307 (16.0) 37,566 (82.4) 
ICS/OCS 7,025 (60.6) 2,616 (22.6) 1,949 (16.8) 52,718 (27.5) 42,821 (22.3) 96,496 (50.2) 
LRA 13,023 (60.6) 4,413 (20.5) 4,065 (18.9) 128,486 (25.9) 101,467 (20.4) 267,085 (53.7) 
MCS 40 (58.8) 17 (25.0) 11 (16.2) 1,121 (35.4) 1,086 (34.3) 963 (30.4) 
Xanthenes 83 (20.3) 28 (6.85) 298 (72.9) 405 (2.46) 383 (2.32) 15,691 (95.2) 
Omalizumab 0 (0) 0 (0) 4 (100) 0 (0) 17 (16.8) 84 (83.2) 
Epinephrine 1,485 (41.0) 1,256 (34.7) 877 (24.2) 14,114 (17.1) 28,147 (34.2) 40,125 (48.7) 
 
Asthma Severity no. (%) 
Intermittent 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 2 (100) 
Mild  26 (61.9) 9 (21.4) 7 (16.7) 249 (1.30) 303 (1.59) 18,551 (97.1) 
Moderate  5,575 (64.9) 1,317 (15.3) 1,495 (17.4) 68,886 (29.4) 41,742 (17.8) 123,497 (52.7) 
Severe 7,426 (56.8) 3,092 (23.6) 2,563 (16.6) 59,373 (24.3) 59,474 (24.4) 125,083 (51.3) 
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Table III presents the characteristic of the levalbuterol and racemic albuterol population 
based on the age group of the patients. Fifty-three percent of the female population of the 
levalbuterol group was between the ages of 0 – 4 years while 65.9% of the racemic albuterol’s 
female population was ≥ 12 years of age. In the levalbuterol group LABA, ICS/OCS 
combination, LRA, and epinephrine were mainly used by the 0 – 4 age group whereas in the 
racemic albuterol group they were mainly used by the ≥ 12 age gro up. In both the levalbuterol 
and racemic groups the majority of LABA/ICS combination, xanthenes, and omalizumab were 
used by the ≥ 12 age group and the majority of MCS was used by the 0 – 4 years age group. In 
the levalbuterol group the majority of patients for each of the severity categories (except 
intermittent) were 0 – 4 years of age whereas in the racemic group the same was true for the ≥ 12 
years age group. 
Table IV presents the expenditure results obtained from the analyses of asthma related 
costs for the population and provides details for medications, emergency department, physician 
and hospitalization trends. Total expenditures are also recorded for both periods and both groups 
of patients. The top portion of the table focuses on our main analysis of asthma-related 
healthcare expenditures, while the bottom portion focused on all healthcare expenditures.  
There was a significant difference in the price of asthma medication with levalbuterol 
patients spending an average of $82 more than the racemic albuterol group (p < 0.001). They 
also spent more on average for hospitalizations but this was not statistically significant (p = 
0.227). The levalbuterol group had a savings of only $5 for pysician visits and $4 for emergency 
department visits. Levalbuterol patients had significantly higher total asthma related 
expenditures than racemic albuterol patients in the 12-month pre-index period ($419 vs $244; p 
<0.001) and 12-month post-index period ($833 vs $569; p = 0.001). Expenditures increased over 
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time for both levalbuterol patients and racemic patients. On average the levalbuterol group had a 
total asthma related healthcare medication costs of $89 more than the racemic albuterol group, 
which was statistically significant (p < 0.001).  
In the bottom portion of table IV, where the focus was total healthcare expenditures for 
the entire sample, the levalbuterol group had an unadjusted savings of $1056 per patient for their 
total healthcare expenditures (p < 0.0001). This was due to the large and statistically significant 
savings of $788 per patient for total healthcare hospitalizations (p < 0.0001). The  levalbuterol 
group on average spent $37 more on medications than the racemic albuterol group but this was 
not statistically significant (p = 0.067). The levalbuterol group also had a statistically significant 
savings of $25 over the racemic albuterol group for emergency department visits (p = 0.0001). 
Table V presents the results obtained from the difference over time regression model that 
was used for the main analysis of ashtma-related healthcare expenditures. The negative 
coefficient (-280.53; t-test p < 0.0001) suggests that trends over time in expenditures were 
statistically lower for levalbuterol users. Asthma related health care costs for patients ages 5 – 11 
years (-79.605; t-test p < 0.0001) and ≥ 12 years (-21.308; t-test p < 0.0001) was statistically less 
compared with patients between the ages of 0 – 4 years. Asthma related healthcare costs for 
females was less compared with men (-7.0008.; t-test p = 0.211) but this was not statistically 
significant. Asthma related healthcare cost for African-Americans was statistically more than 
Whites as suggested by the positive coefficient (62.290; t-test p < 0.0001), and cost for the 
“Other” classification was statistically less than Whites (-327.20; t-test p < 0.0001). All classes 
of drugs except omalizumab increased the asthma healthcare costs as suggested by the positive 
coefficients and P-values <0.05. 
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Table IV. Healthcare expenditures for Medicaid patients with asthma in 12-month pre-and post-index period 
Type of 
Expenditure 
Cost during 12-month pre-index period 
($US) 
Cost during 12-month post-index period 
($US) 
Difference in costs over time 
(post-pre) ($US) 
Difference ($US) 
 Levalbuterol 
(n=16,608) 
Racemic 
albuterol 
(n=205,470) 
t-test 
p-value 
Levalbuterol 
(n=16,608) 
Racemic 
albuterol 
(n=205,470) 
t-test 
p-value 
Levalbuterol 
(n=16,608) 
Racemic 
albuterol 
(n=205,470) 
mean t-test 
p-value 
 
Asthma-related healthcare expenditures (average per patient) 
 
Medication 
 
227.65 101.34 <0.0001 458.75 250.19 <0.0001 231.15 148.85 82.3 <0.0001 
Physician visit 
 
32.962 37.781 <0.0001 76.961 86.810 <0.0001 44.035 49.029 -4.994 0.0089 
ED visits 
 
7.8429 12.046 <0.0001 14.437 22.297 <0.0001 6.5943 10.251 -3.6567 <0.0001 
Hospitalizations 
 
150.37 92.977 <0.0001 282.69 209.59 <0.0001 132.32 116.62 15.7 0.2273 
Total 418.79 244.14 <0.0001 832.84 568.89 <0.0001 414.05 324.75 89.3 <0.0001 
 
All healthcare expenditures (average per patient) 
 
Medication 
 
944.13 1260.8 <0.0001 1935.3 2215.3 <0.0001 991.19 954.51 36.68 0.0667 
Physician visit 
 
986.41 1783.6 <0.0001 1364.5 2440.4 <0.0001 378.07 656.76 -278.69 <0.0001 
ED visits 
 
190.80 324.13 <0.0001 269.77 428.51 <0.0001 78.965 104.39 -25.425 0.0001 
Hospitalizations 
 
3197.8 3717.1 <0.0001 2741.8 4049.3 <0.0001 -456.00 332.21 -788.21 <0.0001 
Total 5319.1 7085.7 <0.0001 6311.3 9133.6 <0.0001 992.22 2047.9 -1055.7 <0.0001 
 
Difference-in-difference corresponds to levalbuterol difference over time minus racemic albuterol difference over time. Negative values in column reflect savings 
associated with levalbuterol use. Positive values reflect losses associated with levalbuterol use 
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Table V:  Asthma-Related health expenditures results obtained from the difference in time regression model 
for Medicaid patients with asthma (F=1442.89) 
Independent variables Parameter 
estimates 
Standard 
error 
t-Score p-Value 95% CI 
Intercept 3507.0 1113.9 3.15 0.002 1323.8, 5690.2 
Levalbuterol user (n=16,608) [vs racemic Albuterol 
use (n=205,470)] -280.53 14.101 -19.89 0.000 -308.17, -252.90 
5 – 11 years (vs. 0 – 4 years) -79.605 8.0791 -9.85 0.000 -95.440, -63.770 
≥ 12 years (vs 0 – 4 years) -21.308 7.1885 -2.96 0.003 -35.397, -7.2188 
Female -7.0008 5.5913 -1.25 0.211 -17.960, 3.9581 
African-American (vs. White) 62.290 8.7406 7.13 0.000 45.159, 79.421 
Hispanic/Latino (vs. White) 18.153 66.478 0.27 0.785 -112.14, 148.45 
Asian or Pacific Islander (vs. White) 81.883 60.335 1.36 0.175 -36.372, 200.14 
Other  (vs. White) -327.20 32.022 -10.22 0.000 -389.96, -264.44 
Not Provided (vs. White) 49.134 10.072 4.88 0.000 29.392, 68.875 
Mild asthma (vs. intermittent asthma) -3203.6 1113.9 -2.88 0.004 -5387.0, -1020.3 
Moderate asthma (vs. intermittent asthma) -3406.8 1113.9 -3.06 0.002 -5590.0, -1223.6 
Severe asthma (vs. intermittent asthma) -3669.9 1113.9 -3.29 0.001 -5853.0, -1486.7 
Long acting beta agonists use 1.9880 0.0233 85.42 0.000 1.9424, 2.0336 
LABA/Corticosteroid combination use 0.8129 0.0205 39.62 0.000 0.7727, 0.8531 
Corticosteroid use 1.3921 0.0179 77.81 0.000 1.3570, 1.4271 
Leukotriene receptor antagonists  use 2.0745 0.0446 46.49 0.000 1.9870, 2.1619 
Mast cell stabilizers use 0.4488 0.0307 14.62 0.000 0.3886, 0.5089 
Xanthene use 1.5278 0.2438 6.27 0.000 1.0498, 2.0054 
Omalizumab use -0.0234 0.0198 -1.18 0.237 -0.0623, 0.0154 
Epinephrine use 2.1645 0.1180 18.34 0.000 1323.8, 5690.2 
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Table VI:  Total health expenditures results obtained from the difference in time regression model for 
Medicaid patients with asthma (F=591.81) 
Independent variables Parameter 
estimates 
Standard 
error 
t-Score p-Value 95% CI 
Intercept 20086 12948 1.55 0.121 -5291.9, 45465 
Levalbuterol user (n=16,608) [vs racemic Albuterol 
use (n=205,470)] -1317.2 163.92 -8.04 0.000 -1638.5, -995.98 
5 – 11 years (vs. 0 – 4 years) 1800.1 93.914 19.17 0.000 1616.1, 1984.2 
≥ 12 years (vs 0 – 4 years) 3812.8 83.562 45.63 0.000 3649.1, 3976.6 
Female 205.04 64.995 3.15 0.002 77.650, 332.43 
African-American (vs. White) -57.366 101.60 -0.56 0.572 -256.50, 141.77 
Hispanic/Latino (vs. White) -950.34 772.76 -1.23 0.219 -2464.9, 564.25 
Asian or Pacific Islander (vs. White) -1092.5 701.36 -1.56 0.119 -2467.1, 282.14 
Other  (vs. White) 1195.0 372.24 3.21 0.001 465.39, 1924.5 
Not Provided (vs. White) -2736.6 117.08 -23.37 0.000 -2966.0, -2507.1 
Mild asthma (vs. intermittent asthma) -20154 12949 -1.56 0.120 -45534, 5225.5 
Moderate asthma (vs. intermittent asthma) -21294 12948 -1.64 0.100 -46672, 4084.3 
Severe asthma (vs. intermittent asthma) -22935 12948 -1.77 0.077 -48312, 2443.3 
Long acting beta agonists use 13.033 0.2705 48.17 0.000 12.502, 13.563 
LABA/Corticosteroid combination use 5.5391 0.2385 23.22 0.000 5.0716,  6.0065 
Corticosteroid use -0.3865 0.2080 -1.86 0.063 -0.7941, 0.0212 
Leukotriene receptor antagonists use 19.504 0.5187 37.60 0.000 18.487, 20.521 
Mast cell stabilizers use 4.9842 0.3569 13.97 0.000 4.2847, 5.6837 
Xanthene use 13.647 2.8336 4.82 0.000 8.0930, 19.201 
Omalizumab use -0.5946  0.2303 -2.58 0.010 -1.0459, -0.1433 
Epinephrine use -13.447 1.3722 -9.80 0.000 -16.136, -10.757 
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Table VI presents the results obtained from the difference over time regression model 
that was used for the analysis of total healthcare expenditures. The negative coefficent (-1317.2; 
p < 0.0001) suggests that trends over time in expenditures were statistically lower for 
levalbuterol users. In this regression analysis the cost of total healthcare for females was 
statistically more compared to men (205.04; t-test p = 0.002). Statistically, more was paid in total 
health care for patients ages 5 – 11 years (1800.1; t-test p < 0.0001) and ≥ 12 years (3812.8; t-test 
p < 0.0001) compared to patients between the ages of 0 – 4 years. The total healthcare cost for 
African-Americans, Hispanics, and Asians were less compared with Whites but they were not 
statistically significant (p = 0.572, 0.219, 0.119 respectively). Total healthcare cost for the 
“Other” category was statistically more compared to Whites (1195.0; t-test p = 0.001). All of the 
classes of drugs except for corticosteroids had a statistical impact on the cost of healthcare as 
suggested by p values <0.0001.  
The results from table VII was used to determine if the use of levalbuterol or racemic 
albuterol had a statistically significant impact in decreasing the number of controller medications 
used, emergency department visits, physician visits, and hospitalizations. This was used as an 
indicator of efficacy since a decrease in any of these could suggest better control of asthma as a 
result of initiating the drug. The results indicate that over the 12 month period medication use for 
both groups decreased in the mild and moderate asthma category but increased for the severe 
category. The change in use of controlling asthma drug over time was statistically significant for 
both groups (p = <0.0001). Asthma related emergency department visits, physician visits and 
hospital visits increased statistically for both groups. All healthcare related emergency 
department visits, physician visits, and hospitalizations  also increased significantly over the 12 
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month period.  These results indicate that neither drug had a significant impact in improving the 
control of asthma. 
 
  
Table VII: Total number Medications other than SABA needed to control 
asthma 
 
 Levalbuterol  
(n=21,511) 
 
Racemic Albuterol  
(n=497,160) 
 Pre-Index 
period 
Post-Index 
Period 
p-value Pre-Index 
period 
Post-Index 
Period 
P-value 
 
Asthma Related 
 
Controlling medications 
0 
(Intermittent) 
1 0  2 3  
1 
(mild) 
42 13 <0.0001 19,103 9,528 <0.0001 
2 
(moderate) 
8,387 4,451  234,125 136,421  
≥3 
(Severe) 
13,081 17,047  243,930 351.208  
 
ED visits 
 
1,324 2,561 <0.0001 47,542 86,105 <0.0001 
Physician visits 
 
9,712 24,694 <0.0001 229,278 552,736 <0.0001 
Hospitalizations 
 
2,099 3,849 <0.0001 32,028 64,656 <0.0001 
 
All Healthcare Related 
 
ED Visits 
 
39,861 55,525 <0.0001 1,147,940 1,503,224 <0.0001 
Physician visits 
 
213,275 295,634 <0.0001 5,553,357 7,460,980 <0.0001 
Hospitalizations 
 
34,367 38,727 <0.0001 720,215 887,907 <0.0001 
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V. Discussion 
 
The results from this experiment suggest that over time the use of levalbuterol results in 
statistically significant savings both in asthma-related and total healthcare cost. The analyses that 
were conducted for this project were split into two major types. First, expenditures that were 
specific to asthma were considered then all healthcare expenditures. Several different approaches 
were used to analyze the data in order to address the perspective of the Medicaid policy maker, 
physician, and others. Medicaid policy makers are most concerned with trends in total healthcare 
expenditures, since Medicaid pays for all such expenditures, not just those for a particular 
disease. Physicians and other clinicians prefer analyses of expenditures that are tied more closely 
to the diseases of interest. 
The two patient populations were very different with the racemic group accounting for 
approximately 23X the size of the levalbuterol group. This study suggests that levalbuterol is 
used more in younger children compared to older children and adults since 61% of the 
levalbuterol group were in the age group 0 – 4 years. The levalbuterol group appeared to have 
more severe asthma than the racemic albuterol group since 60.8% of the levalbuterol group 
compared to the 49.1% of the racemic group had severe asthma as determined by the number of 
controller medications used in the pre-index period.  
The unadjusted difference over time analysis of asthma-related expenditures suggests that 
asthma related expenditures for levalbuterol patients over a year were at least $US89.30 more 
than expenditures for racemic albuterol patients. However, the regression analysis controlling for 
patient characteristic suggests that in fact there is a savings of $US280.53 for levalbuterol 
patients compared to racemic albuterol patients. The results of total healthcare expenditures 
suggests that levalbuterol was the more economical choice since on average patients saved 
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$US1317.2 more than racemic albuterol patients. This was due to a large and statistically 
significant decrease in hospitalization expenditures. This may mean that patients achieved better 
control of their asthma while using levalbuterol versus albuterol which resulted in better control 
of other disease states that can be exacerbated by asthma. Alternatively, it could just be a 
coincidence since the study was not designed to detect correlation between asthma and other 
disease states. The financial results of this study was similar to that of Ozminkowski et al who 
found that levalbuterol use was associated with a savings in total healthcare costs of $US1122. 
However they found that levalbuterol patients on average paid $US853 more for asthma-related 
healthcare cost than racemic albuterol patients. 
The results of table VII suggest that neither levalbuterol nor racemic albuterol was able to 
statistically decrease the number of emergency department visits, physician visits or 
hospitalizations over time. This was also shown in the increase in costs for all of the above from 
the pre-index period to the post-index period in table IV. Although this suggests that neither drug 
was more efficacious compared to the other, important factors such as change in lung function, 
improvement in activities of daily living, safety, patient satisfaction or other important issues 
were not taken into consideration.  
If financial costs rather than efficacy, safety, patient satisfaction, or other issues is what 
drives the market for these drugs then from a purely financial perspective, this study suggests 
that levalbuterol was a more economical choice. Analyses of both asthma-related expenditures 
and total healthcare expenditures favored levalbuterol. This unfortunately does not solve the 
problem as to which drug should be used since the drugs were used in such different population 
and so a direct comparison is not very informative. It is also difficult to determine which drug is 
better from this study since a decrease in healthcare expenditure does not always equal an 
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improvement in healthcare status. Medicaid policy makers may want to use levalbuterol due to 
the overall decrease in costs, whereas physicians and other providers may want to continue to use 
racemic albuterol due to the fact that it has been used for years, it is cheaper for patients and may 
result in better medication adherence and hence better asthma control. 
This study has several limitations. First, this is a retrospective, non-randomized study so data 
could be lost or miscoded. Although multiple regression models were used to control for 
confounding variables, some bias may remain as a result of omitted variables. Secondly, the 
number of levalbuterol users was low compared with the number of racemic Albuterol users. 
While this reflects the market of these two drugs in Kentucky Medicaid patients, greater 
statistical power may have been achieved with a larger patient sample of levalbuterol users. 
Thirdly, this study was limited to Kentucky Medicaid patients with asthma. It is therefore not 
clear whether results can be generalized to other states or to Chronic Obstructive Pulmonary 
Disease (COPD) patients.  
In the analyses of disease-specific expenditures it is impossible to know for certain which 
expenditures were really related to asthma and which expenditures were not. Patients may have 
other chronic conditions and asthma may either complicate these in unknown ways or vice versa. 
Thus, relying on diagnosis codes found in medical claims data may not be ideal for inferring 
whether costs are related to asthma versus other conditions.  
The study is limited because it does not analyze the five components of assessing and 
monitoring asthma control and severity; the intrinsic intensity of the asthma process, the degree 
to which the manifestation of asthma are minimized by therapeutic interventions and the goals of 
therapy are met, the ease with which asthma control is achieved by therapy, frequency and 
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intensity of symptoms and functional limitations the patient experienced, and the likelihood of 
either asthma exacerbation, or progressive decline in lung function (PEF or FEV1) 
 
VI. Recommendations 
 
This study showed that the added cost of using levalbuterol was more than offset by 
reductions in other types of healthcare expenditures. Levalbuterol provides a financial benefit 
over racemic albuterol both in asthma-related and total healthcare costs. It is therefore 
recommended that levalbuterol become the drug of choice for exacerbation of asthma in the 
Kentucky Medicaid population unless adverse effects, patient satisfaction or lung function 
dictates otherwise. Randomized double-blind studies of the Kentucky Medicaid population still 
needs to be done to validate this change in medication preference. A better understanding of the 
impact of levalbuterol use would result from studies of long term use. If total costs are lower for 
levalbuterol patients, then it should be determined whether this is due to fewer adverse effects, 
better adherence or better long-term efficacy. The issue of efficacy would be better addressed by 
a long-term randomized trial that measures the five components of assessing and monitoring 
asthma control and severity and uses FEV1 as a measure of efficacy.  The issue of adverse-effect 
and adherence could be addressed in studies of patient satisfaction.  
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